Completed PHASE1 INTERVENTIONAL 9-arm NCT02055300

Safety, Tolerability and Pharmacokinetics Study of LY03005 (LY03005SAD)

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005

Sponsor: Luye Pharma Group Ltd.

Conditions Major Depressive Disorder

Interventions LY03005 Meal Placebo Pristiq

Updated 6 times since 2017 Last updated: Nov 7, 2014 Started: Feb 28, 2014 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Major Depressive Disorder and is currently completed. Luye Pharma Group Ltd. leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Luye Pharma Group Ltd.

Data source: Luye Pharma Group Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States